Sugi Predict

Sugi Predict / Compounds / SCHEMBL2764016

SCHEMBL2764016

SCHEMBL2764016

CC(C)(C)OC(=O)NC1(C(=O)O)CC1c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ KDM1A O60341 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ ADAMTS5 Q9UNA0 4/20 0.43
▸ RORC P51449 2/20 0.40
▸ FPR1 P21462 1/20 0.39
▸ FPR2 P25090 1/20 0.39
▸ DPP8 Q6V1X1 1/20 0.39
▸ DPP9 Q86TI2 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ PPARA Q07869 1/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899633 1.00 MAPK1 (0.59) MAPK1CYP2C19KDM1AMAOBADAMTS5
SCHEMBL15020639 1.00 MAPK1 (0.59) MAPK1CYP2C19KDM1AMAOBADAMTS5
SCHEMBL2764012 1.00 MAPK1 (0.59) MAPK1CYP2C19KDM1AMAOBADAMTS5
SCHEMBL14265357 1.00 MAPK1 (0.59) MAPK1CYP2C19KDM1AMAOBADAMTS5
SCHEMBL15116474 0.90 MAPK1 (0.48) MAPK1CYP2C19KDM1AMAOBADAMTS5
SCHEMBL15116668 0.90 MAPK1 (0.48) MAPK1CYP2C19KDM1AMAOBADAMTS5
SCHEMBL15116623 0.90 MAPK1 (0.48) MAPK1CYP2C19KDM1AMAOBADAMTS5
SCHEMBL14045956 0.90 MAPK1 (0.48) MAPK1CYP2C19KDM1AMAOBADAMTS5
SCHEMBL15116527 0.90 MAPK1 (0.48) MAPK1CYP2C19KDM1AMAOBADAMTS5
SCHEMBL9556579 0.89 MAPK1 (0.47) MAPK1CYP2C19KDM1AMAOBADAMTS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2024-08-08 — — US disclosed
CN-115038688-A USP30 inhibitors and uses thereof 文森雷生物科学股份有限公司 2022-09-09 — — CN disclosed
EP-4028385-A1 USP30 INHIBITORS AND USES THEREOF Vincere Biosciences, Inc. (US) 2022-07-20 — — EP disclosed
WO-2021050992-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. (US) 2021-03-18 — — WO disclosed
WO-2021050992-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. (US) 2021-03-18 — — WO disclosed
CN-103826661-B Novel binding agent-drug conjugates (ADCs) and uses thereof 西雅图基因公司 2019-03-05 — — CN disclosed
CN-106117312-A New bonding agent drug conjugate (ADC) and application thereof 西雅图基因公司 2016-11-16 — — CN disclosed
US-9056858-B2 Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-06-16 — — US disclosed
EP-2699268-A2 NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE Seattle Genetics, Inc. (US) 2014-02-26 — — EP disclosed
CN-103200950-A Novel auristatin derivatives and use thereof Bayer Pharma AG 2013-07-10 — — CN disclosed
US-20080261994-A1 CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. 2008-10-23 — — US disclosed
US-20080242656-A1 N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof JAPAN TOBACCO INC. 2008-10-02 — — US disclosed
US-7351825-B2 Cyclopropane compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2008-04-01 — — US disclosed
US-20060199826-A1 Cyclopropane compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2006-09-07 — — US disclosed
US-20050222146-A1 N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2005-10-06 — — US disclosed
US-5258362-A Enzyme inhibitors, amides with oxetane ring ABBOTT LABORATORIES (US) 1993-11-02 — — US disclosed
WO-1992022313-A1 RENIN INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1992-12-23 — — WO disclosed
EP-0135429-B1 THE SYNTHESIS OF CYCLOPROPANE AMINO ACIDS AND PEPTIDES THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1992-03-18 — — EP disclosed
EP-0349570-A1 RENIN INHIBITORS CONTAINING A CYCLOPROPYL AMINO ACID AND/OR A CYCLOALKYL TRANSITION-STATE ANALOGUE THE UPJOHN COMPANY (US) 1990-01-10 — — EP disclosed
WO-1988007053-A1 RENIN INHIBITORS CONTAINING A CYCLOPROPYL AMINO ACID AND/OR A CYCLOALKYL TRANSITION-STATE ANALOGUE THE UPJOHN COMPANY (US) 1988-09-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242656-A1 N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof MMP13, MMP11, MMP3 MAPK1 1144/4885CYP2C19 808/4885KDM1A 512/4885
US-20060199826-A1 Cyclopropane compounds and pharmaceutical use thereof MMP13, MMP9, MMP11 MAPK1 2135/4885CYP2C19 158/4885KDM1A 1274/4885
US-20080261994-A1 CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MMP13, MMP9, MMP11 MAPK1 2090/4885CYP2C19 159/4885KDM1A 1248/4885
US-20050222146-A1 N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof MMP13, MMP11, MMP1 MAPK1 1083/4885CYP2C19 755/4885KDM1A 477/4885
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 MAPK1 2205/4885CYP2C19 4475/4885KDM1A 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.